C Diff Treatment Changes
A few weeks ago, a post on Clay Smith’s Journal Feedabout the new IDSA C diff guidelines caught my attention (specifically, that metronidazole is no longer recommended as first line therapy). Whuut? I tweeted this and @medquestioningtweeted back, "Need to dig to see why they dropped metro in the bucket." Yes, @medquestioning, my thoughts exactly.
Mentioned in this episode
- ERcast 2.0launches May 1, 2018
- To sign up for the new site and 1 year of free CME, click here
- Essentials of Emergency Medicineis just around the corner. If you can't make it to Vegas, the digital live stream is pretty sweet.
New IDSA C Diff Guideline Treatment Recommendations
Initial Episode, Non Severe (WBC ≤ 15k, creatinine
First Line
- Vancomycin 125 mg PO QID for 10 days
- Fidaxomicin 200mg PO BID for 10 days
Second line
- Metronidazole 500mg TID PO for 10 days
Initial Episode, Severe (WBC >15k, creatinine >1.5)
- Vancomycin 125 mg PO QID for 10 days
- Fidaxomicin 200mg PO BID for 10 days
Initial Episode, Fulminant (Hypotension or shock, ileus, megacolon)
- Vancomycin 500 mg 4 times per day by mouth or by nasogastric tube.
- If ileus, consider adding rectal instillation of vancomycin.
- Intravenously administered metronidazole (500 mg every 8 hours) should be administered together with oral or rectal vancomycin, particularly if ileus is present
First Recurrence
• Vancomycin 125 mg given 4 times daily for 10 days if metronidazole was used for the initial episode, OR
• Use a prolonged tapered and pulsed vancomycin regimen if a standard regimen was used for the initial episode (eg, 125 mg 4 times per day for 10–14 days, 2 times per day for a week, once per day for a week, and then every 2 or 3 days for 2–8 weeks), OR
• Fidaxomicin 200 mg given twice daily for 10 days if Vancomycin was used for the initial episode
Photo Credit Photo by Gabor Monori on Unsplash
The Guidelines
- McDonald, L. Clifford, et al. "Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)." Clinical Infectious Diseases66.7 (2018): e1-e48. PMID:29462280
Original Studies
- Teasley, DavidG, et al. "Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis." The Lancet322.8358 (1983): 1043-1046. PMID:6138597
- Wenisch, C., et al. "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile—associated diarrhea." Clinical infectious diseases22.5 (1996): 813-818. PMID:8722937
- New Evidence Favoring Vancomycin
- Zar, Fred A., et al. "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity." Clinical Infectious Diseases45.3 (2007): 302-307. PMID:17599306
- Johnson, Stuart, et al. "Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials." Clinical Infectious Diseases 59.3 (2014): 345-354. PMID: 24799326
CDC C. Diff Statistics
New York Times article on the association of the rise of new sweeteners and the rise of C. diff.
